Lyell Immunopharma, Inc.
LYEL
$8.69
-$0.89-9.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.00K | 11.00K | 34.00K | 13.00K | 3.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.00K | 11.00K | 34.00K | 13.00K | 3.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 7.00K | 11.00K | 34.00K | 13.00K | 3.00K |
| SG&A Expenses | 14.05M | 14.52M | 11.77M | 12.26M | 13.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.41M | -1.44M | -730.00K | -976.00K | -1.11M |
| Total Operating Expenses | 56.08M | 61.75M | 50.54M | 51.54M | 55.56M |
| Operating Income | -56.08M | -61.74M | -50.51M | -51.53M | -55.56M |
| Income Before Tax | -52.20M | -191.94M | -44.58M | -45.81M | -60.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.20M | -191.94M | -44.58M | -45.81M | -60.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.20M | -191.94M | -44.58M | -45.81M | -60.67M |
| EBIT | -56.08M | -61.74M | -50.51M | -51.53M | -55.56M |
| EBITDA | -52.64M | -56.72M | -45.83M | -46.63M | -50.54M |
| EPS Basic | -3.54 | -13.71 | -3.48 | -3.59 | -4.77 |
| Normalized Basic EPS | -2.16 | -2.51 | -2.17 | -2.17 | -2.42 |
| EPS Diluted | -3.54 | -13.71 | -3.48 | -3.59 | -4.77 |
| Normalized Diluted EPS | -2.16 | -2.51 | -2.17 | -2.17 | -2.42 |
| Average Basic Shares Outstanding | 14.75M | 14.00M | 12.82M | 12.77M | 12.71M |
| Average Diluted Shares Outstanding | 14.75M | 14.00M | 12.82M | 12.77M | 12.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |